Study of Antitumor Immune Response After cCRT and IO Treatment in Non-resectable III Stage NSCLC Patients

Sponsor
Fundación GECP
Study ID
NCT06634199
Status
Recruiting
Apply to this trial

Conditions

  • Non-small Cell Lung Cancer Stage III
  • PDL1 Gene Mutation

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Durvalumab — DRUG
    Chemo-radiotherapy + Durvalumab for non-resectable stage III NSCLC patients according to clinical practice of each participant hospital

Study Details

Observational, multicenter, one-arm, non-comparative study. Data will be recorded in a retrospectively manner. The study will be based on secondary data collected from patient clinical chart completed by the doctor during routine visits. The primary objective is describe the antitumor immune response generated in the context of IO (immunotherapy) treatment after cCRT in patients with unresectable NSCLC treated in real world.

Key Dates

Start date
Oct 3, 2024
Status verified
Jan 2026
Primary completion
Nov 4, 2027
Completion
Nov 4, 2027

Study Design

Enrollment
50 participants (estimated)

Arms

  • Arm: Observational Study Group
    Real world non-small cell lung cancer (NSCLC) stage IIIA/B and IIIC; PD-L1\>1%; non-resectable patients in treatment with IO after concurrent chemo-radiotherapy without progression.

Primary Outcome Measure

Overall survival (OS) [ Time Frame: To evaluate the Overall Survival at 12, 18, 24 and 36 months ]

Central Contacts

Related Studies